Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[(4- arylpiperazin-1-yl)methyl]-5-substituted-thiophenes. Effect of the 5-modification on allosteric enhancer activity at the A1 adenosine receptor

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7719-7735

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Carrion, Maria Dora ^a   Cara, Carlota Lopez ^a   Cruz Lopez, Olga ^a   Salvador, Maria Kimatrai ^a   Preti, Delia ^a   Tabrizi, Mojgan Aghazadeh ^a   Moorman, Allan R ^b   Vincenzi, Fabrizio ^a   Borea, Pier Andrea ^a   Varani, Katia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b King Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 (4 CHLOROBENZOYL) 4 [(4 ARYLPIPERAZIN 1 YL)METHYL] 5 SUBSTITUTED THIOPHENE DERIVATIVE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; [2 AMINO 4 [(4 BENZYLPIPERAZIN 1 YL)METHYL]5 METHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [(4 PHENYLPIPERAZIN 1 YL)METHYL 5 PHENYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [(4 PHENYLPIPERAZIN 1 YL)METHYL) 5 PHENYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [4 [(4 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL] 5 PHENYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [[4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL]5 METHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [[4 (3,4 DICHLOROPHENYL)PIPERAZIN 1 YL]METHYL]5 METHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [[4 (4 BROMOPHENYL)PIPERAZIN 1 YL]METHYL]5 METHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [[4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL]5 ETHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [[4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL]5 ETHYLTHIOPHEN 3 YL](4 FLUOROPHENYL)METHANONE; [2 AMINO 4 [[4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL]5 METHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [[4 (4 CYANOPHENYL)PIPERAZIN 1 YL]METHYL]5 METHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [[4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL]5 METHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [[4 (4 IODOPHENYL)PIPERAZIN 1 YL]METHYL]5 METHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [[4 (4 METHOXYPHENYL)PIPERAZIN 1 YL]METHYL]5 METHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 4 [[4 [4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL]PIPERAZIN 1 YL]METHYL]5 METHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 5 BROMO 4 [(4 PHENYLPIPERAZIN 1 YL)METHYL]THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 5 BROMO 4 [4 (4 PHENYLPIPERAZIN 1 YL)METHYL]THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 5 BROMO 4 [[4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL]THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 5 ETHYL 4 [(4 PHENYLPIPERAZIN 1 YL)METHYL]THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 5 ETHYL 4 [[4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL]5 ETHYLTHIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 5 METHYL 4 [(4 PHENYLPIPERAZIN 1 YL)METHYL]THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 5 METHYL 4 [[4 (4 METHYLPHENYL)PIPERAZIN 1 YL]METHYL]THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 5 METHYL 4 [[4 (4 NITROPHENYL)PIPERAZIN 1 YL]METHYL]THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 5 METHYL 4 [[4 [3 (TRIFLUOROMETHYL)PHENYL]PIPERAZIN 1 YL]METHYL]THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; [2 AMINO 5 METHYL 4 [[4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERAZIN 1 YL]METHYL]THIOPHEN 3 YL](4 CHLOROPHENYL)METHANONE; ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG SYNTHESIS; ELECTRON TRANSPORT; NONHUMAN;

ALLOSTERIC REGULATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; RECEPTOR, ADENOSINE A1; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THIOPHENES;

EID: 84866321042     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3007504     Document Type: Article

References (39)

1. Jacobson, K. A.; Gao, Z.-G. Adenosine receptors as therapeutic targets Nature Rev. Drug Discovery 2006, 5, 247-264 (Pubitemid 43336037)
2. Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors Pharmacol. Rev. 2001, 53, 527-552 (Pubitemid 33136237)
3. Burnstock, G. Purine and pyrimidine receptors Cell. Mol. Life Sci. 2007, 64, 1471-1483 (Pubitemid 46954150)
4. Van Calker, D. M.; Muller, M.; Hamprecht, B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells J. Neurochem. 1979, 33, 999-1005 (Pubitemid 10188731)
5. Eisenach, J. C.; Hood, D. D.; Curry, R. Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans Anesthesiology 2002, 96, 29-34 (Pubitemid 34032478)
6. 1 receptor-mediated inhibition of myocardial norepinephrine release involves neither phospholipase C nor protein kinase C but does involve adenylyl cyclase Can. J. Physiol. Pharmacol. 2006, 84, 573-577 (Pubitemid 44350532)
7. Fredholm, B. B. Adenosine, an endogenous distress signal, modulates tissue damage and repair Cell. Death Differ. 2007, 14, 1315-1323 (Pubitemid 46965261)
8. Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology Trends Pharmacol. Sci. 2007, 28, 382-389 (Pubitemid 47087967)
9. Milligan, G.; Smith, N. J. Allosteric modulation of heterodimeric G protein-coupled receptors Trends Pharmacol. Sci. 2007, 28, 615-620 (Pubitemid 350166577)
10. Schwartz, T. W.; Holst, B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: Where do they bind and how do they act? Trends Pharmacol. Sci. 2007, 28, 366-373 (Pubitemid 47087971)
11. May, L. T.; Avlani, V. A.; Sexton, P. M.; Christopoulos, A. Allosteric Modulation of G Protein-Coupled Receptors Curr. Pharm. Des. 2004, 10, 2003-2013 (Pubitemid 38842645)
12. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein coupled receptors Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51 (Pubitemid 46277033)
13. Gobylos, A.; Ijzerman, A. P. Allosteric modulation of adenosine receptors Biochem. Biophys. Acta 2011, 1808, 1309-1318
14. Gao, Z.-G.; Kim, S.-K.; Ijzerman, A. P.; Jacobson, K. A. Allosteric modulation of the adenosine family of receptors Mini-Rev. Med. Chem. 2005, 5, 545-553 (Pubitemid 40754168)
15. 1 adenosine receptor Mini-Rev. Med. Chem. 2007, 7, 559-569 (Pubitemid 47099177)
16. Romagnoli, R.; Baraldi, P. G.; Aghazadeh Tabrizi, M.; Gessi, S.; Borea, P. A.; Merighi, S. Allosteric enhancers of A1 adnosine receptors: State of the art and new horizons for drug development Curr. Med. Chem. 2010, 17, 3488
17. 1 receptor binding and function by 2-amino-3-benzoylthiophenes Mol. Pharmacol. 1990, 38, 939-949
18. 1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723 J. Pharmacol. Exp. Ther. 1999, 288, 446-454 (Pubitemid 29119650)
19. 1 receptor Biochem. Pharmacol. 2001, 61, 137-144 (Pubitemid 32121778)
20. Göblyös, A.; IJzerman, A. P. Allosteric modulation of adenosine receptors Purinergic Signalling 2009, 5, 51-61
21. 1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding J. Med. Chem. 1999, 42, 3629-3635 (Pubitemid 29445096)
22. 1 adenosine receptor Bioorg. Med. Chem. Lett. 2000, 10, 1953-1957 (Pubitemid 30663348)
23. 1 adenosine receptors J. Med. Chem. 2002, 45, 382-389 (Pubitemid 34073455)
24. 1 adenosine receptor J. Med. Chem. 2003, 46, 794-809 (Pubitemid 36258870)
25. 1 adenosine agonist binding: New 3,4-, and 5-modifications J. Med. Chem. 2003, 46, 1870-1877 (Pubitemid 36532230)
26. 1 receptor: Synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes J. Med. Chem. 2009, 52, 4543-4547
27. 1 receptors Drug Dev. Res. 2000, 49, 227-237 (Pubitemid 30418419)
28. 1 adenosine receptor allosteric enhancers Bioorg. Med. Chem. 2008, 16, 1319-1327 (Pubitemid 351191773)
29. 1 receptor coupling to G-proteins in brain J. Neurochem. 2005, 93, 715-723 (Pubitemid 40617631)
30. Li, X.; Conklin, D.; Pan, H.-L.; Eisenach, J. C. Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism J. Pharmacol. Exp. Ther. 2003, 305, 950-955 (Pubitemid 36617972)
31. 1 adenosine receptor receptor J. Med. Chem. 2008, 51, 5875-5879
32. Romagnoli, R.; Baraldi, P. G.; Carrion, M. D.; Lopez-Cara, C.; Cruz-Lopez, O.; Kimatrai Salvador, M.; Preti, D.; Aghazadeh Tabrizi, M.; Shryock, J. C.; Moorman, A. R.; Vincenzi, F.; Varani, K.; Borea, P. A. Structure-activity relationships of 2-amino-3-aroyl-4-[(4-arylpiperazin-1-yl) methyl]thiophenes. Part 2. Probing the influence of diverse substituents at the phenyl of the arylpiperazine moiety on allosteric enhancer activity at the A1 adenosine receptor. Bioorg. Med. Chem. 2012, 20,.
33. Gewald, K.; Schinke, E.; Böettcher, H. Heterocycles from CH-acidic nitriles. VIII. 2-Aminothiophenes from methylene-active nitriles, carbonyl compounds and sulfur Chem. Ber. 1966, 99, 94-100
34. Bradford, M. M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding Anal. Biochem. 1976, 72, 248-254
35. 2A adenosine receptors Life Sci. 1996, 59, 1373-1388 (Pubitemid 26344372)
36. 2A receptor ligands Biochem. Pharmacol. 1995, 49, 461-469
37. 3 adenosine receptors Mol. Pharmacol. 2000, 57, 968-975 (Pubitemid 30253381)
38. Munson, P. J.; Rodbard, D. Ligand: A versatile computerized approach for characterization of ligand-binding systems Anal. Biochem. 1980, 107, 220-239
39. 50) of an enzymatic reaction Biochem. Pharmacol. 1973, 1, 3099-3108